Reason for request
Extension of the indication
Clinical Benefit
Clinical Added Value
| moderate |
Given the efficacy of VOTUBIA (everolimus) in reducing renal angiomyolipoma volume associated with tuberous sclerosis complex in adult patients, VOTUBIA provides a substantial improvement in actual benefit (IAB III) in the treatment of patients not requiring immediate surgery (nephrectomy or embolisation). |
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
RfQYS2Tukkvtepet
